Skip to main content
TipRanks
Go Ultimate75% OFF

Apollomics (APLM) AI Stock Analysis

292 Followers
APLM

Apollomics

(NASDAQ:APLM)

Select Model
Rating:40Underperform
Price Target:$18.00â–²(0.90% Upside)
Action:downgraded
Date:11/05/26

APLM scores near the bottom of the range, driven primarily by a fragile financial position: negative shareholders' equity, a shrinking asset base of only $6.7M, zero gross profit on newly recognized revenue, and ongoing cash burn of roughly $10M a year that likely necessitates dilutive financing. Technical signals reinforce the caution, with the stock trading below its 20-, 50- and 100-day moving averages alongside a negative MACD and soft RSI. Valuation offers no cushion given negative earnings and no dividend. The one encouraging element is the sharp year-over-year reduction in losses and cash outflows, suggesting improved cost discipline, but this is not yet enough to offset substantial balance sheet and liquidity risk in this early-stage biotech.

Positive Factors
Revenue ExpansionThe sharp annual revenue increase indicates improved commercial or partnering traction and gives the company a larger base from which to develop its oncology programs. If sustained, this growth could strengthen operating leverage and support broader funding capacity over the next several quarters.
Negative Factors
Persistent Operating LossesLarge operating and net losses show that higher revenue has not yet translated into a profitable business model. Continued losses can consume capital, limit internal investment capacity, and make future progress dependent on successful commercialization or additional funding.

Apollomics (APLM) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%APLM+20.95%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$52.00M
Dividend Yield
―
Average Volume (3M)
12.68K
Price to Earnings (P/E)
-65.9
Beta (1Y)
0.94
Revenue Growth
-100.00%
EPS Growth
99.08%
Country
US
Employees
14
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Apollomics Business Overview & Revenue Model

Company Description

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to d...

Apollomics Financial Statement Overview

Summary

Financial health is very weak across all three statements. The income statement (score 12) shows persistent, deep unprofitability with a -129% net margin in 2025, and although revenue jumped to $8.5M and losses narrowed sharply to ~$10.9M, gross profit fell to zero, undermining the quality of that revenue. The balance sheet (score 8) is the biggest concern: stockholders' equity turned negative at -$3.2M and total assets collapsed from $55.4M in 2023 to just $6.7M, pointing to going-concern and dilution risk despite low absolute debt of $643K. Cash flow (score 15) remains negative at -$10.4M operating and free cash flow, though improved from -$28.7M a year earlier. The narrowing losses and tighter cost base are genuine positives, but liquidity and solvency risks dominate.

Income Statement

12Very Negative

Balance Sheet

8Very Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue8.50M8.50M198.00K821.00K323.00K2,000
Gross Profit8.50M8.24M198.00K821.00K323.00K2,000
EBITDA-9.36M-9.22M-40.77M-52.88M-43.29M-49.59M
Net Income-10.94M-10.94M-53.86M-172.60M-240.81M-94.80M
Balance Sheet
Total Assets6.71M6.71M13.10M55.39M76.47M123.44M
Cash, Cash Equivalents and Short-Term Investments3.28M3.28M9.77M37.82M54.61M94.48M
Total Debt643.00K643.00K966.00K4.66M991.00K325.41M
Total Liabilities9.90M9.90M8.23M14.15M524.60M336.30M
Stockholders Equity-3.19M-3.19M4.86M41.23M-448.12M-212.86M
Cash Flow
Free Cash Flow-17.99M-10.37M-28.77M-43.22M-43.19M-50.86M
Operating Cash Flow-17.99M-10.37M-28.74M-43.21M-42.82M-43.31M
Investing Cash Flow266.00K218.00K5.98M21.36M29.05M-38.95M
Financing Cash Flow3.59M3.68M468.00K21.23M-294.00K-1.64M

Apollomics Technical Analysis

Technical Analysis SentimentNegative
Last Price17.84

Price Trends

50DMA21.62Negative
100DMA21.16Negative
200DMA18.92Negative

Market Momentum

MACD-1.16Positive
RSI38.42Neutral
STOCH17.28Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Negative. The current price of 17.84 is below the 20-day moving average (MA) of 19.67, below the 50-day MA of 21.62, and below the 200-day MA of 18.92, indicating a bearish trend. The MACD of -1.16 indicates Positive momentum. The RSI at 38.42 is Neutral, neither overbought nor oversold. The STOCH value of 17.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APLM.

Apollomics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

APLM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GDTCGDTC43Neutral$9.16M-2.27-91.37%―49.09%3.91%
XCURXCUR42Neutral$7.00M-0.83-237.91%――23.05%
CLGNCLGN41Neutral$6.90M-0.49-215.58%―-86.76%16.63%
APLMAPLM40Underperform$52.00M-65.88103.09%―-100.00%99.08%
HINDHIND39Underperform$10.74M-2.51-73.13%―-96.35%99.68%

* Healthcare Sector Average

Performance Comparison

-50%0%50%APLMHINDCLGNXCURGDTCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
APLM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
APLMApollomics Inc.17.84-0.04-0.22%
HINDVyome Holdings, Inc.1.53-3.08-66.81%
CLGNCollPlant Biotechnologies Ltd.3.65-17.75-82.94%
XCURExicure1.07-3.67-77.43%
GDTCCytoMed Therapeutics Limited0.77-1.04-57.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026